Pharma Clinical Trials & R&D Stage-Gate Valuation Model (2027 Edition)

$99.00

Biotech and pharmaceutical portfolio decision model. Risk-adjusted net present value (rNPV), clinical stage attrition probabilities, patent cliff valuation, and patient recruitment.

🛡️
Institutional Master Model 100% Unlocked Excel Formulas (.xlsx), zero macros or password lockouts.
📊
Board Presentation Deck Automated C-Suite slides & KPI executive summary ready for Board presentation.
📜
Executive Playbook (40+ Pgs) Detailed strategic implementation roadmap, compliance checklists & audit controls.
🏢
Commercial Group License Full authorization to deploy across group subsidiaries and client advisory.
Instant Digital Access

Description

★ Section 1 & 2 • Institutional Executive Overview

Pharma Clinical Trials & R&D Stage-Gate Valuation Model (2027 Edition)

Engineered for Biotech CEOs, Pharma Chief Medical Officers, Life Sciences PE Sponsors, and Licensing Heads. Calculates risk-adjusted Net Present Value (rNPV), clinical phase transition probabilities, and milestone licensing waterfalls.

Pharma Corporate Strategy
Evaluates pipeline asset licensing, milestone buyouts, and patent cliff economics.

Chief Medical Officers (CMO)
Calibrates clinical trial duration, patient recruitment costs, and trial dropouts.

Life Sciences Investors
Builds probabilistic rNPV decision trees across Phase I, II, III, and regulatory review.

Section 3 • Measurable Strategic Outcomes

Strategic Problems Solved & Enterprise Risks Prevented

  • Prevents Capital Over-Allocation: Eliminates static DCF errors by weighting cash flows by empirical clinical success rates.
  • Structures Licensing Milestones: Balances upfront payments, developmental milestones, and tiered net sales royalties.
  • Accelerates Partnering: Formulates institutional 40-slide due diligence pack for big pharma partnering.

Section 4 • Deliverables Inventory

Exact Turnkey Artifacts Included in Download (.ZIP)

XL
Master Pharma rNPV Model (.xlsx)

9 worksheets, 760+ formulas, dynamic clinical transition trees, 100% unlocked.

PT
Licensing & Partnering Deck (.pptx)

40 slides formatted for Pharma BD and Venture Investment committees.

PB
Clinical Stage-Gate Playbook (46 Pages)

FDA/EMA regulatory milestone guide and trial budgeting matrix.

LC
Life Sciences License (.pdf)

Authorized for pipeline asset evaluation and pharma partnering.

Section 5 • Real-Time Calculation Engine
Live Pharma Pipeline rNPV & Clinical Risk Engine


Peak Sales Target ($M)

Current Phase (1=Ph1, 2=Ph2, 3=Ph3)

Cumulative Clinical Success (%)

$2.55B
Unadjusted Peak Value

$238M
Risk-Adjusted rNPV

$65M
Phase 3 Capital Required

Strong Partner Asset
Commercial Viability

Section 6 • Spreadsheet Model Architecture

High-Resolution Excel Worksheet Structure

CenBiz_Pharma_Clinical_rNPV_2027.xlsx [Institutional Structure]
100% Unlocked Excel Formulas
# Worksheet Tab Analytical Function Primary Methodology
1 Pipeline Dashboard Multi-indication portfolio overview and rNPV summary Biopharma Valuation Best Practice
2 Phase Transition Tree Empirical transition probabilities and phase cost schedules Decision Tree rNPV
3 Epidemiological Model Prevalence, incidence, patient capture, and pricing curves Target Product Profile (TPP)
4 Deal Terms & Royalties Upfront payments, developmental milestones, and royalty tiers Pharma Partnering Matrix

Section 7 & 8 • Technical Specs & Codification

Technical Integrity & Global Regulatory Compliance

Software Compatibility

  • Microsoft Excel 365, 2021, 2019, 2016 (PC & Mac)
  • Google Sheets Native Import Verified
  • Zero circular references; 100% unlocked formula integrity
  • Firewall-safe: 0 VBA/macros to prevent corporate proxy quarantine

Regulatory Directives Aligned

  • ICH E6 (R2/R3) Good Clinical Practice (GCP) Guidelines
  • FDA 21 CFR Part 312 (IND) and Part 314 (NDA) Regulations
  • EMA Clinical Trial Regulation (EU) No 536/2014

Section 9 • Practical Execution Guide

90-Day Implementation & Board Cadence

Day 1 – 25
Epidemiology Audit
Validate addressable patient population, dosing regimens, and reimbursement.

Day 26 – 60
Clinical Cost Sizing
Model CRO trial budgets, site count, and enrollment durations.

Day 61 – 90
Partnering Execution
Deliver 40-slide licensing memo to prospective pharmaceutical partners.

Section 10 • Institutional Licensing

Multi-Seat Corporate Licensing Structure

Individual Practitioner
$99
1 Named Executive User
Included with current purchase. Perpetual internal usage rights.

Corporate Team
$299
Up to 10 Seats • Shared Drive
Ideal for departmental finance, PMO, or audit teams.

Business Unit / Division
$699
Up to 50 Seats • Intranet
Division-wide deployment across multiple operating units.

Global Enterprise
$2,450
Unlimited Corporate Entities
Unlimited multinational group internal licensing.

Section 11 & 12 • Executive FAQs & Cross-Pillars

Institutional FAQs & Related Sector Toolkits

Q: Are formulas completely unlocked?
Yes. 100% of cells and formulas are unlocked without passwords, obfuscations, or hidden VBA code.

Q: How are updates distributed for the 2027 edition?
Purchasers receive complimentary revision notifications and updated master archives throughout the entire regulatory edition cycle.

Reviews

There are no reviews yet.

Be the first to review “Pharma Clinical Trials & R&D Stage-Gate Valuation Model (2027 Edition)”